Generic Firms Want Congress To Build On CARES Act To Prevent Critical Drug Shortages
The association for manufacturers of generics and biologics calls for public sector investment in priority medicines.
You may also be interested in...
XGBoost model sees site complexity contributes to quality risk, but misses device-related issues, says third FDA pharmaceutical quality report.
Stand-alone bill headed for Senate, where it fared poorly in coronavirus response legislative packages.
Trump administration infuses Phlow with potentially $800m-plus for fully integrated domestic manufacture of essential medicines for COVID-19 and other crises. Key figures in new approaches to securing drugs and experts on China helped frame the project’s approach.